Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti–PD‐1 in patients with metastatic melanoma
Open Access
Abstract
Background: Melanoma brain metastases (MBM) occur in up to 50% of patients with metastatic melanoma (MM) and represent a frequent site of systemic treatment failure for targeted therapies. However, to the authors' knowledge, little is known regarding the incidence, patterns of disease progression, and outcomes of MBM in patients treated with anti–PD‐1 immunotherapy.Methods: A total of 320 patients with MM who were treated with anti–PD‐1 at The University of Texas MD Anderson Cancer Center in Houston were reviewed. Analyses were performed to identify factors associated with brain metastasis–free survival and overall survival (OS) using Cox regression models.Results: The median age of the patients was 63.3 years. OS from the initiation of anti–PD‐1 therapy was not significantly different between patients without MBM prior to anti–PD‐1 compared with patients with prior MBM (P = .359). Among patients without prior MBM, 21 patients (8.6%) developed MBM during anti–PD‐1 therapy, 12 of whom (4.9%) presented with disease progression in the central nervous system (CNS) only. Developing MBM during or after therapy with anti–PD‐1 (hazard ratio, 4.70; 95% CI, 3.18‐6.93) was associated with shorter OS. Among patients with MBM prior to anti–PD‐1 treatment, 15 (20.0%) progressed in the CNS only and 19 (25.3%) progressed both intracranially and extracranially; at the time of the last data cutoff, 27 patients (36.0%) had not developed disease progression. Radiation necrosis occurred in 11.3% of patients (7 of 62 patients) in the group with a prior MBM who received stereotactic radiosurgery.Conclusions: Anti–PD‐1 therapy may change the natural history of patients with preexisting MBM. However, CNS failure during treatment with anti–PD‐1 is predictive of a worse prognosis compared with extracranial progression. The results of the current study support the activity of anti–PD‐1 in patients with MBM, although routine CNS imaging during therapy is warranted.Keywords
This publication has 28 references indexed in Scilit:
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- The anatomical and cellular basis of immune surveillance in the central nervous systemNature Reviews Immunology, 2012
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialThe Lancet Oncology, 2012
- Epidemiology of Brain MetastasesCurrent Oncology Reports, 2011
- Diagnosis-Specific Prognostic Factors, Indexes, and Treatment Outcomes for Patients With Newly Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4,259 PatientsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Trafficking of immune cells in the central nervous systemJournal of Clinical Investigation, 2010
- CNS metastasis from malignant uveal melanoma: a clinical and histopathological characterisationBritish Journal of Ophthalmology, 2008
- Temozolomide for the Treatment of Brain Metastases Associated With Metastatic Melanoma: A Phase II StudyJournal of Clinical Oncology, 2004
- Determinants of Outcome in Melanoma Patients With Cerebral MetastasesJournal of Clinical Oncology, 2004
- Metastatic pattern of malignant melanomaThe American Journal of Surgery, 1978